---
title: "Seelos Therapeutics (SEEL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/SEEL.US.md"
symbol: "SEEL.US"
name: "Seelos Therapeutics"
industry: "Pharmaceuticals"
datetime: "2026-04-16T22:37:11.116Z"
locales:
  - [en](https://longbridge.com/en/quote/SEEL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/SEEL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/SEEL.US.md)
---

# Seelos Therapeutics (SEEL.US)

## Company Overview

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders. The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease. Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-04-16T04:30:17.000Z

**Overall: C (0.56)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 125 / 188 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 76.05% |  |
| Net Profit YoY | 105.04% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 2014000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -10.86% | D |
| Profit Margin | 203.13% | A |
| Gross Margin | -100.80% | E |
| Revenue YoY | 76.05% | A |
| Net Profit YoY | 105.04% | A |
| Total Assets YoY | -79.97% | E |
| Net Assets YoY | 40.37% | A |
| Cash Flow Margin | 49.23% | C |
| OCF YoY | 76.05% | A |
| Turnover | 0.28 | D |
| Gearing Ratio | 1281.56% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Seelos Therapeutics",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "76.05%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "105.04%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2014000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-10.86%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "203.13%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "-100.80%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "76.05%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "105.04%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-79.97%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "40.37%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "49.23%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "76.05%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.28",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "1281.56%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Eli Lilly (LLY.US) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 03 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 04 | AstraZeneca (AZN.US) | A | B | C | D | B | B |
| 05 | NOVARTIS AG (NVS.US) | A | B | C | D | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/SEEL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/SEEL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/SEEL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/SEEL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**